【摘要】 目的 探讨绝经期促性腺激素及氯米芬在促排卵治疗中适宜的治疗方法。 方法 2004年8月〖CD3/5〗2008年5月对80例不孕患者实施促排卵治疗。测定血雌激素、黄体生成素水平、阴道B型超声、子宫颈黏液评分及基础体温测定监测排卵,并观察不良反应的发生情况。 结果 使用氯米芬及绝经期促性腺激素排卵率分别为773%和856%；卵巢过度刺激综合症发生率为150%,大多由使用绝经期促性腺激素方案引起,且起始剂量150 U；未破裂卵泡黄素化综合征的发生率为90%。 结论 绝经期促性腺激素和氯米芬治疗排卵障碍性不孕有较好的疗效,绝经期促性腺激素和氯米芬促排卵治疗效果与卵巢的状态及激素水平有关。促性腺激素的使用应强调个体化,以达到较好的治疗效果并降低卵巢过度刺激综合症的发生。
【Abstract】 Objective To explore the proper method with human menopausal gonadotropin and clomiphene in facilitating ovulation treatment. Methods Eighty infertility patients with the facilitating ovulation treatment were included from August 2004 to May 2008. Ovulation monitoring was based on the level of estrogen and luteinizing hormone, transvaginal B ultrasound, the cervical Inlser score and assay of basal body temperature. Besides, adverse reactions were observed. Results The rates of ovulation of clomiphene and human menopausal gonadotropin were 77.3% and 85.6%. The rate of ovarian hyperstimulation syndrome (OHSS), which was mostly caused by human menopausal gonadotropin with 150 IU, was 150%. The rate of luteinized unruptured follicle syndrome (LUFS) was 90%. Conclusion Individual therapy with human menopausal gonadotropin and clomiphene is essential to infertility patients with ovulation barrier. The efficacy of human menopausal gonadotropin and clomiphene is relevant to the ovarian condition and the hormone levels. Individual using of hormone is important in the facilitating ovulation treatment, which is helpful to increase the effective efficacy and prevent the OHSS.
Citation： SONG Qi,HAN Ziyan,LIU Hongwei.. The Clinical Experience of Human Menopausal Gonadotropin and Clomiphene in Facilitating Ovulation Treatment. West China Medical Journal, 2010, 25(4): 696-. doi: Copy